Half Year Results 

Hikma back on the upgrade path

Hikma back on the upgrade path

Hikma (HIK) has silenced those who doubted its ability to keep beating expectations by upping its guidance for 2019 following an 11 per cent increase in sales in its generic drugs division in the first half of the year.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now